Study to Evaluate Squalamine Drops for Treatment of Proliferative Diabetic Retinopathy
January 29, 2013
The Elman Retina Group will be studying the efficacy in the use of topical Squalamine Lactate Ophthalmic Solution, 0.2% in the treatment of retinal neovascularization resulting from proliferative diabetic retinopathy.
The primary outcome measure will be the proportion of participants with complete regression of neovascularization on fundus photography at one month.
Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.
The study is not yet recruiting participants.
Read more here.
Jump down to form below to submit your own comments